The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.
Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily WithdrawnApril 15th 2022
The pending biologics license application and supplemental new drug application seeking the approval of the combination of ublituximab and umbralisib in adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma has been voluntarily withdrawn by TG Therapeutics, Inc.
Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLLApril 14th 2022
A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.
First Response Analysis of ALPINE Trial Shows Superior ORR With Zanubrutinib Vs Ibrutinib in CLLApril 11th 2022
Zanubrutinib demonstrated superiority over ibrutinib in terms of overall response rate per independent review committee assessment in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
T-Cell Attributes of Axi-cel Linked to Outcomes in LBCLApril 10th 2022
The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.
FDA Approves Axicabtagene Ciloleucel for Second-Line LBCLApril 1st 2022
The FDA has approved axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
Lisocabtagene Maraleucel sNDA for Second-Line Relapsed/Refractory LBCL Accepted for Review in JapanMarch 26th 2022
The Ministry of Health, Labour, and Welfare has accepted a supplemental new drug application for lisocabtagene maraleucel for the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.
FDA Discourages Pursuit of Marketing Authorization for Zandelisib in MZL, Follicular LymphomaMarch 25th 2022
The FDA has discouraged the pursuit of a marketing authorization of the PI3K inhibitor zandelisib in patients with follicular lymphoma or marginal zone lymphoma, citing the need for randomized trial data.
Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCLMarch 25th 2022
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma.
Tisagenlecleucel Approaches EU Approval for Relapsed/Refractory Follicular LymphomaMarch 25th 2022
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of tisagenlecleucel for use in adult patients with relapsed/refractory follicular lymphoma following 2 lines of systemic treatment.
ZUMA-7 Data Underscore Potential of CAR T-cell Therapy as Second-Line Standard in Relapsed/Refractory LBCL
Frederick Locke, MD, discusses the phase 3 ZUMA-7 trial examining axicabtagene ciloleucel in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, safety and efficacy findings with the therapy, and the significance of the data that have been reported to date.
Increasing Treatment Pathways Pave the Way for Heartening Future Throughout Hematologic MalignanciesMarch 9th 2022
Stephen Oh, MD, PhD, discusses current and emerging agents in myelofibrosis, advances in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, updates in acute and chronic graft-vs-host-disease, and chronic lymphocytic leukemia management.
Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCLFebruary 28th 2022
The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.
Relapsed/Refractory Follicular Lymphoma Has a Bounty of Options in the Third LineFebruary 24th 2022
Caron A. Jacobson, MD, MMSc, and a panel of experts, talk about the evolving landscape for patients with relapsed or refractory follicular lymphoma, plus data on PI3K inhibitors and CAR T-cell therapies.
FDA Investigates Potential Increased Risk of Death With Umbralisib in Select LymphomasFebruary 4th 2022
The FDA has announced that they are investigating umbralisib (Ukoniq), an oral inhibitor of PI3K-delta and CK1-epsilon that is approved to treat patients with marginal zone lymphoma and follicular lymphoma, after initial data from the phase 3 UNITY-CLL trial revealed a potential increased risk of death in those who received the agent.
Zanubrutinib sNDA for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Accepted in ChinaFebruary 1st 2022
The China National Medical Products Administration has accepted a supplemental new drug application for zanubrutinib as a treatment option for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Liso-cel Approaches EU Approval for Relapsed/Refractory DLBCL, PMBCL, and Follicular Lymphoma Grade 3BJanuary 28th 2022
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B following 2 or more lines of systemic therapy.
Venetoclax Shows Impressive Activity in Relapsed/Refractory Waldenström MacroglobulinemiaJanuary 19th 2022
Venetoclax proved to be safe and highly active when used in patients with relapsed or refractory Waldenström macroglobulinemia, including those who previously received BTK inhibitors and those harboring CXCR4 mutations.
Gilead Sciences Withdraws Idelalisib Relapsed Follicular Lymphoma, SLL Indications in the United StatesJanuary 18th 2022
Gilead Sciences, Inc. has decided to voluntarily withdraw the indications of idelalisib in patients with relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma who had received at least 2 prior systemic therapies.
FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCLJanuary 12th 2022
The FDA has granted a regenerative medicine advanced therapy designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma.
Dr. Feldman on Adding Etoposide to Brentuximab Vedotin/CHP in Peripheral T-Cell LymphomasJanuary 10th 2022
Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.